Jump to a particular year :

  • All
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014

News & Events

4P-Pharma est dans l’émission “Les Grands Paris de l’Entreprise”

Revital Rattenbach, présidente et fondatrice de 4P-Pharma, a été interviewée par Céline Bosquet dans l’émission “Les Grands Paris de l’Entreprise” qui sera diffusée le lundi 15 mars 2021 à 19h30 sur Demain TV (canal 31 de la TNT) et à 17h sur BSmart TV et sur BSmart.fr.

Revital présentera 4P-Pharma ainsi que nos dernières actualités sur 4P004, notre traitement pour l’arthrose et 4P021, notre solution contre la COVID-19.

Pour plus d’information : https://www.bsmart.fr/

4Moving Biotech received the Seal of Excellence from the European Commission

4Moving Biotech, our spin-off company centered on 4P004, received the Seal of Excellence from the European Commission, for its application submitted to the Horizon 2020 Accelerator (SME instrument). This award is related to the development of 4P004, our disease modifier treatment for osteoarthritis.

The Seal of Excellence is a high-quality label awarded by a panel of international independent experts. 4Moving Biotech project was scored as a high-quality proposal in a highly competitive evaluation process, it recognizes the high value of our breakthrough treatment at EU level.

Institut de la Vision & 4P-Pharma announce a partnership for the development of an innovative therapy for retinal diseases

4P-Pharma, a clinical-stage biotechnology company and the research center Institut de la Vision (Sorbonne Université, Inserm, CNRS) establish a partnership agreement for the development of 4P020, a promising therapeutic approach for dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech.
This drug candidate, initially studied by Dr Valerie Fontaine at the Institut de la Vision, opens a new therapeutic strategy for these diseases.

“This public-private partnership demonstrates our shared commitment to develop breakthrough and novel therapies that can have a meaningful impact for the millions of patients suffering from dAMD and Stargardt disease worldwide,” says Revital Rattenbach, chairwoman of 4P-Pharma. “Our goal is to accelerate the development of this innovative drug and bring it to the clinic as quickly as possible”.

Valerie Fontaine’s team at IDV
From left to right Elodie MONTEIRO, Thinhinane BOUMEDINE, Valérie FONTAINE, Cécile VIDAL

 

Read the full press release :
EN: 20210128_PR_IDV_Lutech_4P_vEN
FR: 20210128_PR_IDV_Lutech_4P_vFR

Press contact Institut de la Vision
Emanuela De Luca, Scientific Communication and Events
E-mail: emanuela.de-luca@institut-vision.org

Press contact SATT Lutech
Jeanne Gaubert, Technology Licensing Officer
E-mail: jeanne.gaubert@sattlutech.com

Press contact 4P-Pharma
Roselina Lam, Business development and Licensing Manager
E-mail: roselina@4p-pharma.com